Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries - PubMed (original) (raw)
. 1997 Sep;282(3):1650-7.
Affiliations
- PMID: 9316883
Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries
R S Wagner et al. J Pharmacol Exp Ther. 1997 Sep.
Abstract
Pulmonary artery (PA) relaxation in response to vasodilators is significantly attenuated in models of hypoxia-induced pulmonary hypertension (HPH). The activity of phosphodiesterases (PDE) which hydrolyze vasodilatory second messengers may be increased by HPH, which thereby contributes to attenuated vasodilatory responses. The purpose of this study was to determine the effect of PDE inhibition on agonist-induced relaxation of PA from normal rats and rats with HPH (F(IO2), 0.1 for 14 days). Isolated PA rings were suspended in baths containing Krebs-Henseliet salt solution and contracted with U46619 in the presence or absence of a PDE3 (milrinone) or PDE4 (rolipram) inhibitor. Isoproterenol and forskolin induced concentration-dependent relaxation of PA rings from normal rats and rats with HPH, but the degree of relaxation was significantly less (*P < .05; n = 4) in PA from rats with HPH. Treatment with either PDE inhibitor significantly improved (*P < .05; n = 4) the magnitude of agonist-induced relaxation in PA rings from normal rats and rats with HPH. Additionally, PDE3A transcripts (8 and 10 kb) were increased (3.8 +/- 1.6-fold and 3.9 +/- 1.2-fold; n = 3, respectively) in PAs from rats with HPH compared with normal controls. These data show that inhibition of PDE3 and PDE4 activity can significantly improve PA relaxation in HPH and that expression of PDE3A mRNA is increased during HPH. These findings suggest that PDEs play an important role in the development and maintenance of HPH.
Similar articles
- Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone.
Tsai BM, Wang M, Pitcher JM, Kher A, Crisostomo P, Meldrum DR. Tsai BM, et al. Shock. 2005 Nov;24(5):417-20. doi: 10.1097/01.shk.0000183390.98519.05. Shock. 2005. PMID: 16247326 - Phosphodiesterase 5 inhibition restores impaired ACh relaxation in hypertensive conduit pulmonary arteries.
Oka M. Oka M. Am J Physiol Lung Cell Mol Physiol. 2001 Mar;280(3):L432-5. doi: 10.1152/ajplung.2001.280.3.L432. Am J Physiol Lung Cell Mol Physiol. 2001. PMID: 11159025 - Prostanoid TP receptor-mediated impairment of cyclic AMP-dependent vasorelaxation is reversed by phosphodiesterase inhibitors.
Liu CQ, Wong SL, Leung FP, Tian XY, Lau CW, Lu L, Yao X, Chen ZY, Yao T, Huang Y. Liu CQ, et al. Eur J Pharmacol. 2010 Apr 25;632(1-3):45-51. doi: 10.1016/j.ejphar.2010.01.008. Epub 2010 Jan 21. Eur J Pharmacol. 2010. PMID: 20096281 - PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries.
Santos-Silva AJ, Cairrão E, Morgado M, Alvarez E, Verde I. Santos-Silva AJ, et al. Eur J Pharmacol. 2008 Mar 17;582(1-3):102-9. doi: 10.1016/j.ejphar.2007.12.017. Epub 2007 Dec 28. Eur J Pharmacol. 2008. PMID: 18234184 - Role of phosphodiesterases in adult-onset pulmonary arterial hypertension.
Murray F, Maclean MR, Insel PA. Murray F, et al. Handb Exp Pharmacol. 2011;(204):279-305. doi: 10.1007/978-3-642-17969-3_12. Handb Exp Pharmacol. 2011. PMID: 21695645 Review.
Cited by
- Phosphodiesterase in heart and vessels: from physiology to diseases.
Fu Q, Wang Y, Yan C, Xiang YK. Fu Q, et al. Physiol Rev. 2024 Apr 1;104(2):765-834. doi: 10.1152/physrev.00015.2023. Epub 2023 Nov 16. Physiol Rev. 2024. PMID: 37971403 Free PMC article. Review. - Intergenic disease-associated regions are abundant in novel transcripts.
Bartonicek N, Clark MB, Quek XC, Torpy JR, Pritchard AL, Maag JLV, Gloss BS, Crawford J, Taft RJ, Hayward NK, Montgomery GW, Mattick JS, Mercer TR, Dinger ME. Bartonicek N, et al. Genome Biol. 2017 Dec 28;18(1):241. doi: 10.1186/s13059-017-1363-3. Genome Biol. 2017. PMID: 29284497 Free PMC article. - Milrinone relaxes pulmonary veins in guinea pigs and humans.
Rieg AD, Suleiman S, Perez-Bouza A, Braunschweig T, Spillner JW, Schröder T, Verjans E, Schälte G, Rossaint R, Uhlig S, Martin C. Rieg AD, et al. PLoS One. 2014 Jan 31;9(1):e87685. doi: 10.1371/journal.pone.0087685. eCollection 2014. PLoS One. 2014. PMID: 24498166 Free PMC article. Clinical Trial. - Milrinone attenuates thromboxane receptor-mediated hyperresponsiveness in hypoxic pulmonary arterial myocytes.
Santhosh KT, Elkhateeb O, Nolette N, Outbih O, Halayko AJ, Dakshinamurti S. Santhosh KT, et al. Br J Pharmacol. 2011 Jul;163(6):1223-36. doi: 10.1111/j.1476-5381.2011.01306.x. Br J Pharmacol. 2011. PMID: 21385177 Free PMC article. - Targeting dimethylarginine dimethylaminohydrolases in pulmonary arterial hypertension: a new approach to improve vascular dysfunction?
Zweier JL, Talukder MA. Zweier JL, et al. Circulation. 2011 Mar 22;123(11):1156-8. doi: 10.1161/CIRCULATIONAHA.110.017038. Epub 2011 Mar 7. Circulation. 2011. PMID: 21382895 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical